[DOI] [PubMed] [Google Scholar] 300.Kim S., Islam J., Kim J., Koh Y., Hwang J., Kim H.T., Seong S.-Y
In discussions around GLP 1 therapies, Huberman consistently points out that while pharmacology can drive significant fat loss, long term outcomes still depend on training, nutrition, and lifestyle structure
Proposed pathways include modulation of multiple neurotransmitter systems (influencing serotonin, dopamine, norepinephrine, GABA, glutamate levels), possible involvement of NMDA receptors, alpha-1 adrenergic signaling (e.g., potentiating pineal acetyltransferase activity), inhibition of somatostatin release via dopaminergic routes, reduced ACTH/cortisol for stress buffering, and stimulated growth hormone or somatoliberin secretion
Whether you are targeting weight loss specifically or managing concurrent type 2 diabetes, we offer expert consultation to determine the most appropriate medication based on your health profile and goals
Like many of you, I detest feeling sick, and I dread throwing up even more